Cargando…

Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma

Fewer than 50% of patients with high-risk neuroblastoma survive five years after diagnosis with current treatment protocols. Molecular targeted therapies are expected to improve survival. Although MDM2 has been validated as a promising target in preclinical models, no MDM2 inhibitors have yet entere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnhold, Viktor, Schmelz, Karin, Proba, Jutta, Winkler, Annika, Wünschel, Jasmin, Toedling, Joern, Deubzer, Hedwig E., Künkele, Annette, Eggert, Angelika, Schulte, Johannes H., Hundsdoerfer, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788641/ https://www.ncbi.nlm.nih.gov/pubmed/29416773 http://dx.doi.org/10.18632/oncotarget.23409

Ejemplares similares

Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions
por: Schmelz, Karin, et al.
Publicado: (2021)

Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2020)

Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics
por: Lodrini, Marco, et al.
Publicado: (2022)

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017)

Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN
por: Fuchs, Steffen, et al.
Publicado: (2023)

Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging
por: Wu, Zhiyang, et al.
Publicado: (2021)

Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing
por: Szymansky, Annabell, et al.
Publicado: (2021)

Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development
por: da Mota, Vítor Hugo Sales, et al.
Publicado: (2022)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival
por: Thole, Theresa M, et al.
Publicado: (2017)

Adjudication of a Contract for the Sale of a Processor IBM 3032
Publicado: (1981)

The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models
por: Pajtler, Kristian W, et al.
Publicado: (2016)

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2017)

Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect
por: Arlt, Birte, et al.
Publicado: (2021)

Role of intruder configurations in $^{26,28}Ne$ and $^{30,32}Mg$
por: Pritychenko, B V, et al.
Publicado: (1999)

3032 MKit: Pilot Results of Primary Prevention Sexual Violence WebApp
por: Munro-Kramer, Michelle, et al.
Publicado: (2019)

X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
por: Carlet, Michela, et al.
Publicado: (2022)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2015)

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
por: Senapati, Jayastu, et al.
Publicado: (2023)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2016)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
por: Ivasko, Sara Marie, et al.
Publicado: (2023)

Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry
por: Jazmati, Danny, et al.
Publicado: (2022)

Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance
por: Dorel, Mathurin, et al.
Publicado: (2021)

Mutational topography reflects clinical neuroblastoma heterogeneity
por: Rodriguez-Fos, Elias, et al.
Publicado: (2023)

Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4(+) CAR T Cell Efficacy
por: Ali, Solin, et al.
Publicado: (2020)

A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization
por: Grunewald, Laura, et al.
Publicado: (2021)

Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform
por: Wu, Dongwei, et al.
Publicado: (2021)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections - a retrospective matched cohort study
por: Launspach, Michael, et al.
Publicado: (2022)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Basic and clinical immunology – 3032. 18FDG-PET/CT findings (SUV-MAX) are correlated with survival in stage-4 squamous cell carcinoma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer
por: Stumbryte, Ausra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4o5pd9c9i2r1kas6ij8o2gh4s8